Medical News

RSS

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.

22 Feb 2011

Michael & Susan Dell Foundation grants $3.7 million to UTHealth for child obesity prevention, research

To continue their efforts to fight childhood obesity, The Michael & Susan Dell Center for Healthy Living, part of The University of Texas Health Science Center at Houston, has been awarded a four-year grant for $3.7 million grant from the Michael & Susan Dell Foundation.

22 Feb 2011

House votes to defund Planned Parenthood

On the same day as the House vote, the White House narrowed a Bush administration rule that allows medical providers to refuse to perform abortions.

22 Feb 2011

Claraview's Healthcare Analytics Solutions is now available for hospitals, clinics and health insurers

Claraview, a division of Teradata Corporation, a strategy and technology consultancy focused on business intelligence and analytics, today announced the availability of its Healthcare Analytics Solutions for hospitals, clinics, physician-practices, long-term care facilities, pharmacy benefit managers and health insurers.

22 Feb 2011

'Day on Deadly Killers'

Experts from Europe, the US and Asia will present their research results and discuss how new therapeutical approaches against infectious diseases may look like.

22 Feb 2011

Study: High-quality hospitals deliver lower-cost care to trauma patients

High-quality hospitals deliver lower-cost care to trauma patients, according to a study published in the Annals of Surgery.

22 Feb 2011

Canadian Intellectual Property Office grants patent to CardioGenics' QL Care Analyzer

CardioGenics Holdings Inc. announced today that it has been notified by the Canadian Intellectual Property Office that its patent application for the "core technology" utilized in its ultra-sensitive point-of-care immuno-analyzer, the QL Care Analyzer, has been granted. Patents covering the "core technology" have now been issued in Canada, the European Union and Japan.

22 Feb 2011

House passes FY11 budget bill

The House voted 235-189 on Saturday to pass legislation that "would fund government operations through Sept. 30, the end of fiscal 2011, while sharply reducing spending across a wide swath of federal agencies and programs," CQ reports. "Most spending levels under the bill would be based on fiscal 2010 levels, less eliminations, reductions and rescissions totaling roughly $61.5 billion. The measure would provide $99.6 billion less than President Obama sought for fiscal 2011," the news service writes (Weyl, 2/19).

22 Feb 2011

Researcher finds antibiotic in Eastern Red Cedar tree effective against MRSA

Most people would never suspect that a "trash tree," one with little economic value and often removed by farmers due to its ability to destroy farmland, could be the key to fighting a deadly bacterium. Now, a University of Missouri researcher has found an antibiotic in the Eastern Red Cedar tree that is effective against methicillin-resistant Staphylococcus aureus, a "superbug" that is resistant to most medications.

22 Feb 2011

Novartis FLUAD seasonal flu vaccine for older adults receives Health Canada approval

Health Canada has approved FLUAD, a Novartis seasonal flu vaccine for adults 65 years and older. Canadian seniors are the hardest hit of all age groups by seasonal influenza and account for 90 per cent of influenza deaths and 70 per cent of hospitalizations.

22 Feb 2011

NanoString launches fixed-panel assay product for human molecular karyotyping

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the first fixed-panel assay product to be developed on its Copy Number Variation detection platform - the nCounter Human Karyotype Panel.

From NanoString Technologies 22 Feb 2011

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of a Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II.

22 Feb 2011

Researchers find endothelial dysfunction can predict risk of coronary heart disease

A new study from the Libin Cardiovascular Institute at the University of Calgary's Faculty of Medicine is shedding light on an underlying cause of heart disease.

22 Feb 2011

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination with gemcitabine in patients with previously untreated, metastatic, pancreatic cancer.

22 Feb 2011

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.

22 Feb 2011

Health Canada approves Orexo's Abstral to treat chronic cancer pain

Orexo AB today announces that ProStrakan's partner, Paladin Labs Inc. has been informed by Health Canada, the Canadian Government Department with responsibility for public health, that it has approved Abstral.

22 Feb 2011

Forest Labs enters definitive merger agreement to acquire Clinical Data

Forest Laboratories, Inc. and Clinical Data, Inc. today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd.

22 Feb 2011

KemPharm commences KP201 Phase 1 trial for pain

KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers with KP201, its novel abuse deterrent prodrug of hydrocodone for pain. KP201 is a new chemical entity and is the most advanced opioid-based lead candidate in KemPharm's emerging pipeline.

22 Feb 2011

FDA clears ArthroCare's Parallax Contour-enhanced Vertebral Augmentation Device

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today that it has received clearance from the U.S. Food and Drug Administration to market its second-generation Parallax Contour -enhanced Vertebral Augmentation Device specifically for void creation in a vertebral body followed by injection of bone cement.

22 Feb 2011

Autism could be detected earlier and easier: Study

Scientists at Boston may have found the beginnings of a non-invasive diagnostic test that can detect abnormal brain waves that suggest increased risk for autism – a debilitating neurological disorder in babies. This test would be safe, inexpensive, and easy to perform and could make it possible for at-risk kids to get help right away rather than having to wait until months or years later, which is now the case with the behavioral tests believe experts.

22 Feb 2011

Medical News

Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD

Michael & Susan Dell Foundation grants $3.7 million to UTHealth for child obesity prevention, research

House votes to defund Planned Parenthood

Claraview's Healthcare Analytics Solutions is now available for hospitals, clinics and health insurers

'Day on Deadly Killers'

Study: High-quality hospitals deliver lower-cost care to trauma patients

Canadian Intellectual Property Office grants patent to CardioGenics' QL Care Analyzer

House passes FY11 budget bill

Researcher finds antibiotic in Eastern Red Cedar tree effective against MRSA

Novartis FLUAD seasonal flu vaccine for older adults receives Health Canada approval

NanoString launches fixed-panel assay product for human molecular karyotyping

TransPharma completes ViaDor-GLP1 agonist Phase 1b trial for treatment of type II diabetes

Researchers find endothelial dysfunction can predict risk of coronary heart disease

Infinity commences IPI-926 Phase 2 trial in patients with pancreatic cancer

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Health Canada approves Orexo's Abstral to treat chronic cancer pain

Forest Labs enters definitive merger agreement to acquire Clinical Data

KemPharm commences KP201 Phase 1 trial for pain

FDA clears ArthroCare's Parallax Contour-enhanced Vertebral Augmentation Device

Autism could be detected earlier and easier: Study

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News